Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age18-70
SponsorVanda Pharmaceuticals
About this trial
Primary Objective: To treat a single patient with gastroparesis who has requested expanded access with tradipitant
Eligibility criteria
Qualifiers
Identified subject who requested expanded access
Diagnosed with gastroparesis
Demonstrated delayed gastric emptying
Presence of moderate to severe nausea
Disqualifiers
Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis
A positive test for drugs of abuse at the screening or evaluation visits;
Exposure to any investigational medication in the past 60 days other than tradipitant
Gastrectomy, fundoplication, vagotomy, pyloroplasty, bariatric surgery, or gastric stimulation device surgically implanted within the last year
Trial design
Treatments tested in this trial
- Tradipitant
Treatment groups
No treatment groups listed
Locations
15Florida
Vanda Investigational Site32751, Maitland United States
Vanda Investigational Site33613, Tampa United States
Illinois
Vanda Investigational Site60084, Wauconda United States
Kansas
Vanda Investigational Site67214, Wichita United States
Sponsors and collaborators
Vanda Pharmaceuticals
Lead sponsor
Source ClinicalTrials.gov